Wang Yuanping, Li Xiaohui, Li Ziqing, Zhang Yu, Wang Dawei
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou Shunde Hospital Affiliated of Guangzhou University of Chinese Medicine, Shunde, China.
Medicine (Baltimore). 2018 Feb;97(8):e9957. doi: 10.1097/MD.0000000000009957.
Chronic heart AQ4 failure (CHF) is the final stage of various heart diseases. YiQiFuMai injection (YQFMI) has been widely applied in the treatment of CHF. However, to our knowledge, there has been no systematic review or meta-analysis of randomized controlled trails (RCTs) regarding the effectiveness of this treatment. Here, we provide a protocol to evaluate the efficacy and safety of YQFMI for CHF.
To evaluate the clinical efficacy of YQFMI in treating CHF, 2 researcher members will independently search the RCTs in the following 8 Chinese and English databases, in which the data collection will be from the time when the respective databases were established to January 2018. The databases will include MEDLINE, EMBASE, Cochrane CENTRAL, CINAHL, the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, VIP Information and Wanfang Data. The therapeutic effects according to the mortality and the New York Heart Association (NYHA) function classification will be accepted as the primary outcomes. We will use RevMan V.5.3 software as well to compute the data synthesis carefully when a meta-analysis is allowed.
This study will provide a high-quality synthesis of current evidence of YQFMI for CHF from several aspects including mortality, NYHA function classification.
The conclusion of our systematic review will provide evidence to judge whether YQFMI is an effective intervention for CHF.PROSPERO registration number: PROSPERO CRD42017079696.
慢性心力衰竭（CHF）是各种心脏病的终末期。益气复脉注射液（YQFMI）已广泛应用于CHF的治疗。然而，据我们所知，尚未有关于该治疗效果的随机对照试验（RCT）的系统评价或荟萃分析。在此，我们提供一项方案以评估YQFMI治疗CHF的疗效和安全性。
为评估YQFMI治疗CHF的临床疗效，两名研究人员将独立检索以下8个中英文数据库中的RCT，数据收集时间为各数据库建立至2018年1月。这些数据库将包括MEDLINE、EMBASE、Cochrane CENTRAL、CINAHL、中国生物医学文献数据库、中国知网、维普资讯和万方数据。根据死亡率和纽约心脏协会（NYHA）功能分级的治疗效果将作为主要结局。当允许进行荟萃分析时，我们还将使用RevMan V.5.3软件仔细计算数据合成。
本研究将从死亡率、NYHA功能分级等多个方面对YQFMI治疗CHF的现有证据进行高质量的综合分析。
我们系统评价的结论将为判断YQFMI是否为CHF的有效干预措施提供证据。
PROSPERO CRD42017079696。
